MX2011009821A - Derivados de isotiazolo pirimidinadiona como moduladores del trpa1. - Google Patents
Derivados de isotiazolo pirimidinadiona como moduladores del trpa1.Info
- Publication number
- MX2011009821A MX2011009821A MX2011009821A MX2011009821A MX2011009821A MX 2011009821 A MX2011009821 A MX 2011009821A MX 2011009821 A MX2011009821 A MX 2011009821A MX 2011009821 A MX2011009821 A MX 2011009821A MX 2011009821 A MX2011009821 A MX 2011009821A
- Authority
- MX
- Mexico
- Prior art keywords
- acetamide
- dioxo
- tetrahydro
- dimethyl
- thiazolo
- Prior art date
Links
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 title 1
- CBFZADDDBQLSPS-UHFFFAOYSA-N [1,2]thiazolo[4,3-d]pyrimidine 2,2-dioxide Chemical class N1=CN=CC2=NS(=O)(=O)C=C21 CBFZADDDBQLSPS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 201000010099 disease Diseases 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 66
- -1 cyano, hydroxyl Chemical group 0.000 claims 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 208000002193 Pain Diseases 0.000 claims 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 150000005347 biaryls Chemical group 0.000 claims 3
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229910052801 chlorine Chemical group 0.000 claims 2
- 239000000460 chlorine Chemical group 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 230000003349 osteoarthritic effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 150000000177 1,2,3-triazoles Chemical class 0.000 claims 1
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- KCAZYBRGKJKRLO-UHFFFAOYSA-N N-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC(=CS1)C1=CC(=C(F)C=C1)C(F)(F)F KCAZYBRGKJKRLO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- PBMQQKUDOPKOMR-UHFFFAOYSA-N n-[4-[3-fluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(C=2C=C(F)C(=CC=2)C(F)(F)F)=C1 PBMQQKUDOPKOMR-UHFFFAOYSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 2
- 230000001052 transient effect Effects 0.000 abstract 2
- KFPREKBZXDIMQJ-UHFFFAOYSA-N [1,2]thiazolo[3,4-d]pyrimidine 2,2-dioxide Chemical compound C1=NC=NC2=NS(=O)(=O)C=C21 KFPREKBZXDIMQJ-UHFFFAOYSA-N 0.000 abstract 1
- AMKLYVPTLKOMBX-UHFFFAOYSA-N [1,2]thiazolo[5,4-d]pyrimidine 1,1-dioxide Chemical class N1=CN=C2S(=O)(=O)N=CC2=C1 AMKLYVPTLKOMBX-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN665MU2009 | 2009-03-23 | ||
| US17135509P | 2009-04-21 | 2009-04-21 | |
| PCT/IB2010/000834 WO2010109328A1 (en) | 2009-03-23 | 2010-03-22 | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009821A true MX2011009821A (es) | 2012-01-25 |
Family
ID=42236291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009821A MX2011009821A (es) | 2009-03-23 | 2010-03-22 | Derivados de isotiazolo pirimidinadiona como moduladores del trpa1. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8575178B2 (enExample) |
| EP (1) | EP2411397B1 (enExample) |
| JP (1) | JP2012521405A (enExample) |
| KR (1) | KR20120001746A (enExample) |
| CN (1) | CN102395592A (enExample) |
| AP (1) | AP2011005888A0 (enExample) |
| AU (1) | AU2010227224A1 (enExample) |
| BR (1) | BRPI1009372A2 (enExample) |
| CA (1) | CA2756534A1 (enExample) |
| DK (1) | DK2411397T3 (enExample) |
| EA (1) | EA201190191A1 (enExample) |
| ES (1) | ES2424340T3 (enExample) |
| IL (1) | IL215179A0 (enExample) |
| MX (1) | MX2011009821A (enExample) |
| PE (1) | PE20120764A1 (enExample) |
| PL (1) | PL2411397T3 (enExample) |
| PT (1) | PT2411397E (enExample) |
| SG (2) | SG174403A1 (enExample) |
| SI (1) | SI2411397T1 (enExample) |
| UA (1) | UA107342C2 (enExample) |
| WO (1) | WO2010109328A1 (enExample) |
| ZA (1) | ZA201107646B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010227225A1 (en) | 2009-03-23 | 2011-09-15 | Glenmark Pharmaceuticals, S.A. | Furopyrimidinedione derivatives as TRPA1 modulators |
| SG174402A1 (en) | 2009-03-23 | 2011-10-28 | Glenmark Pharmaceuticals Sa | Fused pyrimidine-dione derivatives as trpa1 modulators |
| US8592398B2 (en) | 2010-12-20 | 2013-11-26 | Glenmark Pharmaceuticals, S.A. | 2-amino-4-arylthiazole compounds as TRPA1 antagonists |
| EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| RU2014100744A (ru) | 2011-06-13 | 2015-07-20 | Гленмарк Фармасьютикалс С.А. | Лечение респираторных нарушений с помощью trpa1 антагонистов |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| JP2014517062A (ja) | 2011-06-22 | 2014-07-17 | グレンマーク ファーマシューティカルズ， エセ．アー． | ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物 |
| WO2013014597A1 (en) | 2011-07-25 | 2013-01-31 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| TWI640519B (zh) * | 2011-11-29 | 2018-11-11 | 泰緯生命科技股份有限公司 | Ｈｅｃ１活性調控因子及其調節方法 |
| JP2015500278A (ja) | 2011-12-05 | 2015-01-05 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔｒｐａ１アンタゴニストと抗コリン剤とを含む医薬組成物 |
| MX354014B (es) | 2012-06-08 | 2018-02-08 | Glenmark Pharmaceuticals Sa | Amidas de compuestos de 2-amino-4-ariltiazol y sus sales. |
| SI2903965T1 (sl) | 2012-10-01 | 2017-07-31 | Orion Corporation | Derivati n-prop-2-inil karboksamida in njihova uporaba kot antagonisti trpa1 |
| CA2884767A1 (en) | 2012-11-14 | 2014-05-22 | Stephan Bachmann | Imidazopyridine derivatives |
| HK1221161A1 (zh) | 2013-06-20 | 2017-05-26 | Glenmark Pharmaceuticals S.A. | 包含trpa1拮抗剂的纳米颗粒制剂 |
| CA2926389A1 (en) | 2013-10-15 | 2015-04-23 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent |
| WO2015155306A1 (en) * | 2014-04-11 | 2015-10-15 | Almirall, S.A. | New trpa1 antagonists |
| US20190175599A1 (en) | 2014-09-16 | 2019-06-13 | Glemark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| WO2018233648A1 (zh) * | 2017-06-21 | 2018-12-27 | 南京明德新药研发股份有限公司 | 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物 |
| CN112794860B (zh) * | 2021-03-24 | 2021-06-29 | 上海肇钰医药科技有限公司 | 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途 |
| CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2248231A1 (de) * | 1972-10-02 | 1974-04-11 | Basf Ag | 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| AU2003290066A1 (en) | 2002-12-18 | 2004-07-09 | Novartis Ag | Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| WO2005077959A1 (en) * | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| US20070196866A1 (en) | 2004-03-13 | 2007-08-23 | Irm Llc | Modulators of ion channel trpa1 |
| US20090062258A1 (en) | 2005-02-03 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
| JP5858557B2 (ja) * | 2005-12-22 | 2016-02-10 | ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | 疼痛を処置するためのｔｒｐａ１阻害剤 |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| WO2009002933A1 (en) * | 2007-06-22 | 2008-12-31 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
| WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
-
2010
- 2010-03-22 MX MX2011009821A patent/MX2011009821A/es unknown
- 2010-03-22 WO PCT/IB2010/000834 patent/WO2010109328A1/en not_active Ceased
- 2010-03-22 PE PE2011001703A patent/PE20120764A1/es not_active Application Discontinuation
- 2010-03-22 KR KR1020117023383A patent/KR20120001746A/ko not_active Withdrawn
- 2010-03-22 EP EP10716049.1A patent/EP2411397B1/en not_active Not-in-force
- 2010-03-22 ES ES10716049T patent/ES2424340T3/es active Active
- 2010-03-22 AP AP2011005888A patent/AP2011005888A0/xx unknown
- 2010-03-22 US US13/257,241 patent/US8575178B2/en not_active Expired - Fee Related
- 2010-03-22 SG SG2011066495A patent/SG174403A1/en unknown
- 2010-03-22 EA EA201190191A patent/EA201190191A1/ru unknown
- 2010-03-22 SI SI201030232T patent/SI2411397T1/sl unknown
- 2010-03-22 CA CA2756534A patent/CA2756534A1/en not_active Abandoned
- 2010-03-22 PT PT107160491T patent/PT2411397E/pt unknown
- 2010-03-22 SG SG2012069464A patent/SG184766A1/en unknown
- 2010-03-22 CN CN2010800168801A patent/CN102395592A/zh active Pending
- 2010-03-22 BR BRPI1009372A patent/BRPI1009372A2/pt not_active IP Right Cessation
- 2010-03-22 DK DK10716049.1T patent/DK2411397T3/da active
- 2010-03-22 PL PL10716049T patent/PL2411397T3/pl unknown
- 2010-03-22 JP JP2012501411A patent/JP2012521405A/ja not_active Withdrawn
- 2010-03-22 AU AU2010227224A patent/AU2010227224A1/en not_active Abandoned
- 2010-03-23 UA UAA201111149A patent/UA107342C2/ru unknown
-
2011
- 2011-09-15 IL IL215179A patent/IL215179A0/en unknown
- 2011-10-19 ZA ZA2011/07646A patent/ZA201107646B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG174403A1 (en) | 2011-10-28 |
| PL2411397T3 (pl) | 2013-10-31 |
| EA201190191A1 (ru) | 2012-11-30 |
| JP2012521405A (ja) | 2012-09-13 |
| KR20120001746A (ko) | 2012-01-04 |
| EP2411397B1 (en) | 2013-05-29 |
| PT2411397E (pt) | 2013-06-06 |
| US20120010223A1 (en) | 2012-01-12 |
| HK1166081A1 (en) | 2012-10-19 |
| EP2411397A1 (en) | 2012-02-01 |
| ZA201107646B (en) | 2012-06-25 |
| SI2411397T1 (sl) | 2013-07-31 |
| PE20120764A1 (es) | 2012-06-27 |
| AU2010227224A1 (en) | 2011-09-29 |
| AU2010227224A2 (en) | 2011-10-27 |
| US8575178B2 (en) | 2013-11-05 |
| CA2756534A1 (en) | 2010-09-30 |
| CN102395592A (zh) | 2012-03-28 |
| ES2424340T3 (es) | 2013-10-01 |
| SG184766A1 (en) | 2012-10-30 |
| AP2011005888A0 (en) | 2011-10-31 |
| IL215179A0 (en) | 2011-12-29 |
| UA107342C2 (en) | 2014-12-25 |
| BRPI1009372A2 (pt) | 2016-05-31 |
| WO2010109328A1 (en) | 2010-09-30 |
| DK2411397T3 (da) | 2013-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011009821A (es) | Derivados de isotiazolo pirimidinadiona como moduladores del trpa1. | |
| MX2011009822A (es) | Derivados de tienopirimidinadiona como moduladores del trpa1. | |
| JP2012521405A5 (enExample) | ||
| JP2012521401A5 (enExample) | ||
| AU2009265362B2 (en) | Chemical compounds 251 | |
| AU2010204118B2 (en) | Sulfonamide derivatives | |
| JP4972690B2 (ja) | 脂質レベルの上昇に関連する疾病の処置に適するヘテロ環式化合物 | |
| JP4906738B2 (ja) | キナーゼインヒビターとして有用な、フェニル置換ピリミジン化合物 | |
| MX2011009824A (es) | Derivados de pirimidina-diona fusionados como moduladores del trpa1. | |
| RU2005105696A (ru) | Замещенные тиенилгидроксамовые кислоты в качестве ингибиторов гистондеацетилазы | |
| WO2008057775A2 (en) | Heterocyclic amide compounds useful as kinase inhibitors | |
| CA2545711A1 (en) | Urea derivatives as kinase modulators | |
| EA035500B1 (ru) | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b | |
| PL195955B1 (pl) | Związek, pochodna benzenosulfonamidu, sposób jegowytwarzania, kompozycja farmaceutyczna zawierająca go oraz jego zastosowanie | |
| WO2002062804A1 (en) | Oxazolyl-pyrazole derivatives as kinase inhibitors | |
| AU2002246076A1 (en) | Oxazolyl-pyrazole derivatives as kinase inhibitors | |
| CA2540541A1 (en) | Alkoxy substituted imidazoquinolines | |
| KR20120096076A (ko) | 스핑고신 키나아제 저해제 | |
| SK20182000A3 (sk) | Činidlo regulujúce funkciu receptora súvisiaceho s retinoidmi | |
| JP2012515789A (ja) | スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体 | |
| EA027351B1 (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления | |
| WO2004101529A1 (ja) | 含窒素複素環化合物およびその医薬用途 | |
| RU2019114964A (ru) | Терапевтические средства и способы их применения | |
| JPH0273069A (ja) | エチレンジアミンモノアミド誘導体 | |
| EP3137461B1 (en) | Method of preparing an optically active pde10 inhibitor |